Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX therapy in Japan: A retrospective observational study using administrative database.
Authors
Yu Sunakawa
Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan
Yu Sunakawa , Chaochen Wang , Yongzhe Piao , Long Jin , Yoshinori Tanizawa , Zhihong Cai , Yoshinori Kagawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 110)
DOI
10.1200/JCO.2024.42.3_suppl.110
Abstract #
110
Poster Bd #
G14
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Prospective multicenter study of the impact of the 12-gene assay recurrence score on adjuvant chemotherapy treatment recommendations for stage II/III colon cancer in the post-IDEA era: SUNRISE-Decision Impact study.
First Author: Takeharu Yamanaka
Poster
2024 ASCO Gastrointestinal Cancers Symposium
The efficacy of chemotherapy for colorectal cancer with early recurrence after adjuvant chemotherapy.
First Author: Dai Okemoto
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FOLFOXIRI ± molecular targeting agent (bevacizumab or panitumumab) for conversion from unresectable to resectable in the advanced/recurrent colorectal cancer.
First Author: Kodai Takemori
First Author: Sandra Algaze